Fidelity Select Biotechnology Portfolio EBIT

Fidelity Select Biotechnology Portfolio (FBIOX) currently reports a EBIT of $-1.4M as of September 2023. That compares with $-23M in the prior-year period — up 93.6% year over year. That is above the sector sector average of $-9.6M. Use the charts on this page to explore Fidelity Select Biotechnology Portfolio's EBIT history and peer comparisons.

Fidelity Select Biotechnology Portfolio's EBIT increased from $-23M to $-1.4M — a 93.6% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fidelity Select Biotechnology Portfolio's EBIT of $-1.4M is higher than the its sector sector average of $-9.6M. That is roughly 85.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Fidelity Select Biotechnology Portfolio reported $-1.4M in EBIT as of September 2023. That compares with $-23M in the prior-year period — up 93.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-9.6M. From there, open related valuation or income-statement pages for Fidelity Select Biotechnology Portfolio, and consider following FBIOX for alerts when major investors trade the stock.